0001437749-19-006477.txt : 20190403
0001437749-19-006477.hdr.sgml : 20190403
20190403163035
ACCESSION NUMBER: 0001437749-19-006477
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190401
FILED AS OF DATE: 20190403
DATE AS OF CHANGE: 20190403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wrighton-Smith Peter
CENTRAL INDEX KEY: 0001592286
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36200
FILM NUMBER: 19729387
MAIL ADDRESS:
STREET 1: C/O OXFORD IMMUNOTEC GLOBAL PLC
STREET 2: 94C INNOVATION DRIVE
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oxford Immunotec Global PLC
CENTRAL INDEX KEY: 0001586049
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
BUSINESS PHONE: 44 01235 442780
MAIL ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
4
1
rdgdoc.xml
FORM 4
X0306
4
2019-04-01
0001586049
Oxford Immunotec Global PLC
OXFD
0001592286
Wrighton-Smith Peter
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE
X0
OX14 4RZ
UNITED KINGDOM
1
1
Chief Executive Officer
Ordinary Shares
2019-04-01
4
A
0
31669
0
A
445138
D
Ordinary Shares
2019-04-01
4
S
0
10000
16.6446
D
435138
D
Ordinary Shares
2019-04-01
4
S
0
600
17.2096
D
434538
D
Share Option (Right to Buy)
16.42
2019-04-01
4
A
0
67959
0
A
2029-04-01
Ordinary Shares
67959
67959
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Options granted under Issuer's 2013 Share Incentive Plan
Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2020 through January 1, 2023.
/s/ Elizabeth M. Keiley, as Attorney-in-Fact for Peter Wrighton-Smith
2019-04-03